NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 25, 2022, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2021.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
Date: March 25, 2022
Time: 8:30 AM Eastern Time
Toll Free: 888-506-0062; Entry Code: 938572
International: 973-528-0011; Entry Code: 938572
The call will also be available over the Internet and accessible at:
https://www.webcaster4.com/Webcast/Page/2475/44898
About Delcath Systems, Inc.
In Europe, the PHP system is now regulated as a Class lll medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
Contact:
Delcath Investor Relations
Email: [email protected]
Hayden IR
James Carbonara
(646)-755-7412
[email protected]
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
